Colombia’s compulsory license can expand access to HIV drug dolutegravir

Certain clauses in the trade deal could dilute use of public health measures under Indian patent law.

Millions of people around the world rely on affordable generic medicines and vaccines produced in India, the ‘Pharmacy of the Developing World’

MSF welcomes the Indian Commerce Ministry’s strong stand against the inclusion of data exclusivity in its free trade agreement talks with the European Free Trade Association (EFTA).

Leaked text shows India-EFTA trade deal includes excessive intellectual property provisions that may require India to gut pro-public health national laws, which may undermine people's access to affordable medicines from India

Union CL draft proposal will only allow supply and use of products within EU countries

Colombia plans to issue compulsory license on HIV drug dolutegravir, expanding access

MSF calls on J&J not to enforce secondary patents on TB drug bedaquiline, to improve global access to this lifesaving medicine

MSF signed onto a letter supporting Colombia’s action to possibly issue a compulsory license to improve access to HIV drug dolutegravir

MSF appreciates EC pharma legislation proposal to improve transparency by industry and the granting of compulsory licenses on medicines in the EU.

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely

MSF comments on EU's Supplementary Protection Certificates (SPC) system that unnecessarily extend pharmaceutical corporations’ monopolies, keeping lifesaving medicines out of people’s hands.

Amidst the ongoing global crisis caused by the COVID-19 pandemic, the United States Trade Representative (USTR) released its annual “Special 301 Report” targeting countries for implementing and supporting public health safeguard in ...

“India should be cautious while signing any trade package or launching trade negotiations with the US that may include harmful provisions threatening India’s ability to produce and supply affordable medical products. Going by past ...

While we welcome the recent withdrawal of harmful provisions from the IP chapter of RCEP, namely patent term extensions and data exclusivity, Japan’s strong push for elevated IP enforcement measures continues to be a matter of grave ...

Most recent Priority Review Voucher is a reminder of why Congress should reform the US government program to only reward companies for developing new and affordable drugs and vaccines for neglected diseases

As ministers and leaders from member countries gather in Singapore this week, Japan and South Korea continue to push India and the ten member states of ASEAN to agree to IP provisions that undermine generic competition.